JP Morgan Maintains Underweight on Myriad Genetics, Raises Price Target to $20
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Rachel Vatnsdal maintains an Underweight rating on Myriad Genetics (NASDAQ:MYGN) but raises the price target from $17 to $20.
August 07, 2024 | 5:43 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
JP Morgan analyst Rachel Vatnsdal maintains an Underweight rating on Myriad Genetics (NASDAQ:MYGN) but raises the price target from $17 to $20.
The Underweight rating suggests a cautious outlook, but the raised price target indicates some positive expectations. The mixed signals are likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100